Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KOMET: selumetinib in adults with symptomatic, inoperable plexiform neurofibromas in NF1
CTR20220093Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in neurofibromatosis type 1 (NF1) and plexiform neurofibroma (PN) comparing Selumetinib with Placebo (2 arms). Primary endpoint: Objective response rate. Started Apr 2022; status: completed.
02
Drugs
selumetinib
03
Conditions
neurofibromatosis type 1 (NF1)plexiform neurofibroma (PN)
Beyond the preview
Go deeper on CTR20220093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220093.